Sanofi is developing strategies to control beta cell destruction in type 1 diabetes (T1D) through immunotherapy. Strategies could include targeting specific molecules on cells that may be of importance in disease pathogenesis. Such approaches are in progress and candidate molecular targets of potential interest have been identified. As part of the next steps, our goal […]